Mitragynine (Kratom), Confirmation
CPT Code(s):
80357
Turnaround Time:
24 - 72 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
1.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present
Stability Criteria
Room Temperature:
24 hours
Refrigerated:
7 days
Frozen:
30 days
Clinical Significance
Mitragynine with quantitative results using liquid chromatography-tandem mass spectrometry (LC/MS-MS) holds specific clinical significance and diagnostic use in measuring the concentration of mitragynine in a patient's biological sample. Mitragynine is the primary alkaloid found in Kratom, a plant native to Southeast Asia that is used for its stimulant and analgesic properties.
The specific clinical significance and diagnostic use of Mitragynine include:
1. Toxicology Screening: Mitragynine is a psychoactive compound that has gained popularity as a recreational drug and a potential alternative to opioids for pain management. Mitragynine with quantitative results is used for toxicology screening to detect and quantify the presence of mitragynine in a patient's sample. It helps in identifying mitragynine use, monitoring for misuse or abuse, and assessing potential overdose situations.
2. Forensic Investigations: Mitragynine plays a role in forensic investigations and legal proceedings. It provides objective evidence of mitragynine use or exposure, aiding law enforcement agencies, forensic laboratories, and legal professionals in investigating drug-related incidents, conducting drug testing, and providing evidence in legal cases involving mitragynine.
3. Clinical Management: Quantitative results from Mitragynine assist healthcare providers in monitoring patients who may be using mitragynine-based products for pain management or other purposes. It helps in assessing patient compliance, optimizing therapeutic outcomes, and ensuring appropriate dosing.
4. Research and Epidemiology: Mitragynine using LC/MS-MS contributes to research and epidemiological studies focused on understanding the prevalence, patterns, and impact of mitragynine use. It provides valuable data on mitragynine concentrations in different populations, helping researchers and public health officials to assess the risks and benefits associated with its use.
Interpretation of the quantitative results of Mitragynine should consider the patient's clinical context, drug history, and the specific mitragynine concentrations detected. Monitoring mitragynine levels helps ensure medication adherence, evaluate treatment effectiveness, and detect potential risks associated with its use.
In summary, Mitragynine with quantitative results using LC/MS-MS is specifically used for toxicology screening, forensic investigations, clinical management, and research purposes. It provides valuable information about the presence and concentration of mitragynine, aiding healthcare providers, forensic experts, researchers, and legal professionals in various aspects related to mitragynine use and exposure. Collaboration between laboratory professionals, healthcare providers, researchers, and other relevant stakeholders is crucial for accurate interpretation of the test results and appropriate patient care.
CPT Code(s):
80357
Turnaround Time:
24 - 72 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
1.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present
Stability Criteria
Room Temperature:
24 hours
Refrigerated:
7 days
Frozen:
30 days
Clinical Significance
Mitragynine with quantitative results using liquid chromatography-tandem mass spectrometry (LC/MS-MS) holds specific clinical significance and diagnostic use in measuring the concentration of mitragynine in a patient's biological sample. Mitragynine is the primary alkaloid found in Kratom, a plant native to Southeast Asia that is used for its stimulant and analgesic properties.
The specific clinical significance and diagnostic use of Mitragynine include:
1. Toxicology Screening: Mitragynine is a psychoactive compound that has gained popularity as a recreational drug and a potential alternative to opioids for pain management. Mitragynine with quantitative results is used for toxicology screening to detect and quantify the presence of mitragynine in a patient's sample. It helps in identifying mitragynine use, monitoring for misuse or abuse, and assessing potential overdose situations.
2. Forensic Investigations: Mitragynine plays a role in forensic investigations and legal proceedings. It provides objective evidence of mitragynine use or exposure, aiding law enforcement agencies, forensic laboratories, and legal professionals in investigating drug-related incidents, conducting drug testing, and providing evidence in legal cases involving mitragynine.
3. Clinical Management: Quantitative results from Mitragynine assist healthcare providers in monitoring patients who may be using mitragynine-based products for pain management or other purposes. It helps in assessing patient compliance, optimizing therapeutic outcomes, and ensuring appropriate dosing.
4. Research and Epidemiology: Mitragynine using LC/MS-MS contributes to research and epidemiological studies focused on understanding the prevalence, patterns, and impact of mitragynine use. It provides valuable data on mitragynine concentrations in different populations, helping researchers and public health officials to assess the risks and benefits associated with its use.
Interpretation of the quantitative results of Mitragynine should consider the patient's clinical context, drug history, and the specific mitragynine concentrations detected. Monitoring mitragynine levels helps ensure medication adherence, evaluate treatment effectiveness, and detect potential risks associated with its use.
In summary, Mitragynine with quantitative results using LC/MS-MS is specifically used for toxicology screening, forensic investigations, clinical management, and research purposes. It provides valuable information about the presence and concentration of mitragynine, aiding healthcare providers, forensic experts, researchers, and legal professionals in various aspects related to mitragynine use and exposure. Collaboration between laboratory professionals, healthcare providers, researchers, and other relevant stakeholders is crucial for accurate interpretation of the test results and appropriate patient care.
CPT Code(s):
80357
Turnaround Time:
24 - 72 hours
Specimen Requirements
Preferred Specimen:
Urine
Minimum Volume:
1.0 mL
Transport Container:
Yellow Top Tube or Sterile Cup
Transport Temperature:
Room Temperature
Collection Instructions:
Collect urine in plastic container and transfer to plain yellow top tube (without preservative).
Rejection Criteria:
Specimen received outside stability requirements; Excessive blood, particulates, viscosity present
Stability Criteria
Room Temperature:
24 hours
Refrigerated:
7 days
Frozen:
30 days
Clinical Significance
Mitragynine with quantitative results using liquid chromatography-tandem mass spectrometry (LC/MS-MS) holds specific clinical significance and diagnostic use in measuring the concentration of mitragynine in a patient's biological sample. Mitragynine is the primary alkaloid found in Kratom, a plant native to Southeast Asia that is used for its stimulant and analgesic properties.
The specific clinical significance and diagnostic use of Mitragynine include:
1. Toxicology Screening: Mitragynine is a psychoactive compound that has gained popularity as a recreational drug and a potential alternative to opioids for pain management. Mitragynine with quantitative results is used for toxicology screening to detect and quantify the presence of mitragynine in a patient's sample. It helps in identifying mitragynine use, monitoring for misuse or abuse, and assessing potential overdose situations.
2. Forensic Investigations: Mitragynine plays a role in forensic investigations and legal proceedings. It provides objective evidence of mitragynine use or exposure, aiding law enforcement agencies, forensic laboratories, and legal professionals in investigating drug-related incidents, conducting drug testing, and providing evidence in legal cases involving mitragynine.
3. Clinical Management: Quantitative results from Mitragynine assist healthcare providers in monitoring patients who may be using mitragynine-based products for pain management or other purposes. It helps in assessing patient compliance, optimizing therapeutic outcomes, and ensuring appropriate dosing.
4. Research and Epidemiology: Mitragynine using LC/MS-MS contributes to research and epidemiological studies focused on understanding the prevalence, patterns, and impact of mitragynine use. It provides valuable data on mitragynine concentrations in different populations, helping researchers and public health officials to assess the risks and benefits associated with its use.
Interpretation of the quantitative results of Mitragynine should consider the patient's clinical context, drug history, and the specific mitragynine concentrations detected. Monitoring mitragynine levels helps ensure medication adherence, evaluate treatment effectiveness, and detect potential risks associated with its use.
In summary, Mitragynine with quantitative results using LC/MS-MS is specifically used for toxicology screening, forensic investigations, clinical management, and research purposes. It provides valuable information about the presence and concentration of mitragynine, aiding healthcare providers, forensic experts, researchers, and legal professionals in various aspects related to mitragynine use and exposure. Collaboration between laboratory professionals, healthcare providers, researchers, and other relevant stakeholders is crucial for accurate interpretation of the test results and appropriate patient care.